| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 30, 2026 4:00 P.M. |
| Form: | F-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 30, 2026 4:00 P.M. |
| Form: | F-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2025 | $23.00 | Buy | D. Boral Capital |
| 9/8/2023 | $14.50 | Buy | Alliance Global Partners |
| 1/5/2023 | $21.00 | Overweight | Cantor Fitzgerald |
Initial deployment is expected to include six Nanox.ARC systems under a capex model PETACH TIKVA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (("Nanox", NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced a distribution agreement with Top Med SAC ("Top Med") to deploy the Nanox.ARC system and related services in Peru. Under the agreement, Nanox appointed Top Med as its exclusive distributor of the Nanox.ARC system and Nanox platform in Peru, subject to commercial milestones and regulatory requirements. The agreement is structured as a capex model and includes an expected initial deployment of six Nanox.ARC systems, subject to receipt of t
AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifyi
Advances Nanox's ongoing U.S. commercialization and deployment efforts PETACH TIKVA, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Nano X Imaging Ltd. (("Nanox", or the "Company", NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has signed a distribution agreement with NuvioDx LLC ("NuvioDx"), an imaging solutions provider focused on expanding access to diagnostic imaging, to support the deployment of Nanox.ARC systems. This agreement represents Nanox's growing distribution framework announced in 2026, following recent agreements, as the company continues to advance its channel partner strategy and build a dive
4 - Nano-X Imaging Ltd. (0001795251) (Issuer)
D. Boral Capital initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $23.00
Alliance Global Partners initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $14.50
Cantor Fitzgerald initiated coverage of Nano-X Imaging with a rating of Overweight and set a new price target of $21.00
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
SCHEDULE 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
20-F - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) -- NANOX IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products. "Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field," stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. "As we
Advanced commercialization in the US, signing multiple new customer and distribution agreements for Nanox.ARC and accelerated activities around Nanox.AI Management to host conference call and webcast Monday, April 20, 2026 at 8:30 AM ET Appointed new CFO effective August 1, 2026 PETAH TIKVA, Israel, April 20, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2025, and provided a business update. Recent Highlights: Generated $3.7 million in revenue in the fourth quarter of 2025, compared to $3.0 million in the fourth quarter o
PETACH TIKVA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended December 31, 2025, before market open on Monday, April 20, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 2025 Call The live webcast of the conference call may be accessed by using t
Management to host conference call and webcast Thursday, November 20, 2025, at 8:30 AM ET Company advances commercialization and is on track to meet year-end system deployment target PETAH TIKVA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2025, and provided a business update. Recent Highlights: Generated $3.4 million in revenue in the third quarter of 2025, compared to $3.0 million in the third quarter of 2024.Acquired 100% of the stock of Vaso Healthcare IT, a provider of healthcare information technologies solu
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)